Study Timeline

2018 2017 2016 | 2015 | 2014 | 2013 | 2012 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006-2002 |


June 2018: Reached 2 million downloads of PPMI data.

October 2018: Advanced Analytics Core added to the study.

December 2018: PPMI enrollment goals are reached and formal recruitment is closed.



June 2017: PPMI protocol is updated to extend visits through 2023.

November 2017: Genetic Registry closes.



January 2016: PPMI study protocol updated, allowing for continued participation for subjects in the Parkinson’s Disease and Health Control cohorts through 2018 and including an ancillary study to collect blood samples for the generation of induced pluripotent stem cells (iPSC) at select sites

April 2016: PPMI Protocol is updated, allowing for the integration of a quantitative measure of gait and mobility to be performed on enrolled PPMI subjects at select participating clinical trial sites.



August 2015: PPMI team kicks off wide spread recruitment campaign to enroll genetic cohort subjects

February 2015: PPMI has now received 50 requests for biospecimens

March 2015: Launch of the expansion of the genetic cohort to study individuals with a GBA mutation

March 2015Enrollment of prodromal cohort completed



January 2014: First subjects enrolled in the PPMI genetic cohort and in the PPMI genetic registry

February 2014: Launch of the genetic cohort and registry to investigate the link between LRRK2 and SNCA genetic mutations and Parkinson’s

2014: PPMI expands to Israel, New York City, and France



February 2013: Launch of prodromal cohort to investigate risk factors of PD: hypsomia, REM behavior sleep disorder (RBD), and the presence of a LRRK2 genetic mutation

April 2013: Enrollment of de novo PD, control, and SWEDD cohorts completed

July 2013: First subject enrolled in the Prodromal Cohort of PPMI

September 2013: PPMI Genetics Cohort Kick-Off meeting held in New York, NY

September 2013: First PPMI Study Update Call for participants

November 2013: Reached 100,000 downloads of the PPMI data

2013: PPMI expands to Greece, Spain, and Norway



January 2012: 300 of the 600 subjects needed for PPMI are actively enrolled in the study

March 2012: PPMI expands to a third continent, Australia. One site is selected to participate in the study

Spring 2012: PPMI Steering Committee begins discussion of the addition of a new Pre-Motor PD cohort

Fall 2012: PPMI Steering Committee begins planning for the addition of a pre-motor cohort to the study



March 2011: access to study data and specimens becomes available coinciding with 50 subjects having completed baseline visits

August 2011: : PPMI adds a third cohort: Subjects with SWEDD (Scans without Evidence of Dopamanergic Deficit)

September 2011: First Study Update Dinner for PPMI participants held in New Haven, Connecticut.

December 2011: First PPMI primary publication is published



January 2010: Steering Committee meeting to finalize Protocol and discuss data flow and SOPs

March 2010: Investigators Meeting brings together members of the steering committee, study cores, clinical sites and MJFF; study protocols, tests and assessment details, recruitment and retention plans and outcomes are discussed

April 2010: First PPMI protocol goes into effect

June 2010: PPMI recruitment begins; first PPMI subject is enrolled



June 2009: Protocol Task force is appointed; begins to define study design

August 2009: Steering Committee is formed

September 2009: Study Cores are selected

October 2009: Workshop to further refine core selection, define site selection process and set a timeline for study design and launch; verification study is conducted



May 2008: Workshop to define study objectives, criteria for site selection and other study parameters



February 2007: The Michael J. Fox Foundation (MJFF) Scientific Advisory Board holds a formal discussion on the need for a concerted biomarker effort

June 2007: Workshop to explore feasibility, required  scientific expertise and MJFF’s role in a large-scale biomarkers study

October 2007: Workshop to further define the scientific cores that would be needed to support a large scale biomarkers study



MJFF sponsored three biomarker RFA’s and supported applications exploring clinical, imaging and biochemical biomarkers that would be useful in clinical trials